0001628280-24-006985.txt : 20240226
0001628280-24-006985.hdr.sgml : 20240226
20240226193407
ACCESSION NUMBER: 0001628280-24-006985
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240222
FILED AS OF DATE: 20240226
DATE AS OF CHANGE: 20240226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HANLY ANN M.
CENTRAL INDEX KEY: 0001854528
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39083
FILM NUMBER: 24681320
MAIL ADDRESS:
STREET 1: C/O VIR BIOTECHNOLOGY, INC.
STREET 2: 499 ILLINOIS STREET, SUITE 500
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vir Biotechnology, Inc.
CENTRAL INDEX KEY: 0001706431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 812730369
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 OWENS STREET
STREET 2: SUITE 900
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-906-4324
MAIL ADDRESS:
STREET 1: 1800 OWENS STREET
STREET 2: SUITE 900
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
4
1
wk-form4_1708994010.xml
FORM 4
X0508
4
2024-02-22
0
0001706431
Vir Biotechnology, Inc.
VIR
0001854528
HANLY ANN M.
C/O VIR BIOTECHNOLOGY, INC.
1800 OWENS STREET, SUITE 900
SAN FRANCISCO
CA
94158
0
1
0
0
EVP & Chief Technology Officer
1
Common Stock
2024-02-22
4
A
0
32500
0
A
147076
D
Common Stock
2024-02-22
4
S
0
12296
10.0456
D
134780
D
Common Stock
11.52
I
See footnote
Stock Option (Right to Buy)
10.11
2024-02-22
4
A
0
65000
0
A
2034-02-21
Common Stock
65000
65000
D
Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.
25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly
installments thereafter.
/s/ Sung Lee, Attorney-in-Fact
2024-02-26